- Open
- 0.47
- High
- 0.50
- Low
- 0.45
- Close
- 0.45
- Change
- -0.02 (-5.26%)
- Volume
- 841,828
⌘K
| 10 Apr 2026 | 15:24:21 | Holding(s) in Company |
| 7 Apr 2026 | 17:20:02 | Holding(s) in Company |
| 31 Mar 2026 | 07:00:12 | Board Change |
| 30 Mar 2026 | 09:10:44 | Holding(s) in Company |
| 5 Feb 2026 |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 31 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Verici Dx utilizes advanced sequencing technology to create a customized risk assessment for kidney transplant patients throughout their treatment, while also identifying potential damage earlier than traditional clinical and pathological methods.
| 10 Apr 2026 | 15:24:21 | Holding(s) in Company |
| 7 Apr 2026 | 17:20:02 | Holding(s) in Company |
| 31 Mar 2026 | 07:00:12 | Board Change |
| 30 Mar 2026 | 09:10:44 | Holding(s) in Company |
| 5 Feb 2026 |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 31 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Verici Dx utilizes advanced sequencing technology to create a customized risk assessment for kidney transplant patients throughout their treatment, while also identifying potential damage earlier than traditional clinical and pathological methods.
| 07:01:00 |
| FY25 Trading Update |
Lord Stevens of Ludgate has interests in this issuer
| 07:01:00 |
| FY25 Trading Update |
Lord Stevens of Ludgate has interests in this issuer